Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
Université Fédérale de Toulouse Midi-Pyrénées · Hôpital Saint-Louis · +21 more institutions
Indexed incrossrefpubmed
Abstract
Background
Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell transplantation (ASCT) may be useful.
Methods
sensitivity before maintenance therapy.
Citation impact
51
total citations
- FWCI
- 66.35
- Percentile
- 100%
- References
- 22
Citations per year
Authors
26Topics & keywords
Topics
Keywords
- Residual
- Multiple myeloma
- Medicine
- Minimal residual disease
- Disease
- Internal medicine
- Computer science
- Bone marrow
UN Sustainable Development Goals
- Zero hunger
No related works found for this paper.